Assembly Falls Well Short In Attempt At Finite HBV Therapy
Executive Summary
Biotech tried to show that a core inhibitor combined with standard hepatitis B therapy could yield lasting benefit after treatment. Vebicorvir will continue to be studied as a chronic treatment in HBV.
You may also be interested in...
Gilead Adds To Virology Focus Through 12-Year Collaboration With Assembly
Gilead gets option rights to Assembly’s entire virology pipeline, including future assets, for herpesvirus and hepatitis B and D. The deal provides financial stability and opt-in potential for Assembly.
Big Pharma Pacts Benefit From Reduced HBV Biologics Competition
Partnerships between big pharma and biotech focused on biologic therapies for hepatitis B could reap the benefit of less competition as lone biotechs, such as Aligos, discontinue their candidates.
Assembly Looks To Quickly Move Past ABI-H2158 Discontinuation
The company’s triple-combination studies with vebicorvir and next-generation core inhibitor programs may hold more promise in hepatitis B.